Literature DB >> 25480944

TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.

Yang Peng1, Hui Dai2, Edward Wang1, Curtis Chun-Jen Lin2, Wei Mo2, Guang Peng3, Shiaw-Yih Lin4.   

Abstract

BRCA1 expression is lost frequently in breast cancers in which it promotes malignant development. In the present study, we performed a global expression analysis of breast cancer cells in which the tumor-suppressor candidate gene TUSC4 was silenced to gain insights into its function. TUSC4 silencing affected genes involved in cell cycle and cell death, which have broad reaching influence on cancer development. Most importantly, we found a cluster pattern of gene-expression profiles in TUSC4-silenced cells that defined a homologous recombination (HR) repair defect signature. Mechanistic investigations indicated that TUSC4 protein could physically interact with the E3 ligase Herc2, which prevents BRCA1 degradation through the ubiquitination pathway. TUSC4 silencing enhanced BRCA1 polyubiquitination, leading to its degradation and a marked reduction in HR repair efficiency. Notably, ectopic expression of TUSC4 suppressed the proliferation, invasion, and colony formation of breast cancer cells in vitro and tumorigenesis in vivo. Furthermore, TUSC4 silencing was sufficient to transform normal mammary epithelial cells and to enhance sensitivity to PARP inhibitors. Our results provide a set of genetic and biologic proofs that TUSC4 functions as a bona fide tumor suppressor by regulating the protein stability and function of BRCA1 in breast cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25480944      PMCID: PMC4804342          DOI: 10.1158/0008-5472.CAN-14-2315

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains.

Authors:  Y Jin; X L Xu; M C Yang; F Wei; T C Ayi; A M Bowcock; R Baer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  BRCA1 is a cell cycle-regulated nuclear phosphoprotein.

Authors:  H Ruffner; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

3.  Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage.

Authors:  R Scully; J Chen; R L Ochs; K Keegan; M Hoekstra; J Feunteun; D M Livingston
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

4.  The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells.

Authors:  Kentaro Ueda; Hiroyuki Kawashima; Shoichiro Ohtani; Wu-Guo Deng; Murali Ravoori; Jim Bankson; Boning Gao; Luc Girard; John D Minna; Jack A Roth; Vikas Kundra; Lin Ji
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

Review 5.  Mechanism of homologous recombination: mediators and helicases take on regulatory functions.

Authors:  Patrick Sung; Hannah Klein
Journal:  Nat Rev Mol Cell Biol       Date:  2006-08-23       Impact factor: 94.444

Review 6.  Tumor suppressors and cell metabolism: a recipe for cancer growth.

Authors:  Russell G Jones; Craig B Thompson
Journal:  Genes Dev       Date:  2009-03-01       Impact factor: 11.361

7.  Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C.

Authors:  Jingfeng Li; Fuli Wang; Klas Haraldson; Alexey Protopopov; Fuh-Mei Duh; Laura Geil; Igor Kuzmin; John D Minna; Eric Stanbridge; Eleonora Braga; Vladimir I Kashuba; George Klein; Michael I Lerman; Eugene R Zabarovsky
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

8.  TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling.

Authors:  Atsuo Kurata; Ryohei Katayama; Toshiki Watanabe; Takashi Tsuruo; Naoya Fujita
Journal:  Cancer Sci       Date:  2008-07-04       Impact factor: 6.716

Review 9.  BRCA1, a potential predictive biomarker in the treatment of breast cancer.

Authors:  Colin R James; Jennifer E Quinn; Paul B Mullan; Patrick G Johnston; D Paul Harkin
Journal:  Oncologist       Date:  2007-02

Review 10.  Basal-like breast cancer and the BRCA1 phenotype.

Authors:  N C Turner; J S Reis-Filho
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

View more
  14 in total

Review 1.  Functional and pathological relevance of HERC family proteins: a decade later.

Authors:  Susana Sánchez-Tena; Monica Cubillos-Rojas; Taiane Schneider; Jose Luis Rosa
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

2.  Personalised pathway analysis reveals association between DNA repair pathway dysregulation and chromosomal instability in sporadic breast cancer.

Authors:  Chao Liu; Sriganesh Srihari; Samir Lal; Benoît Gautier; Peter T Simpson; Kum Kum Khanna; Mark A Ragan; Kim-Anh Lê Cao
Journal:  Mol Oncol       Date:  2015-09-26       Impact factor: 6.603

3.  Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia.

Authors:  Rupert L Mayer; Josef D Schwarzmeier; Marlene C Gerner; Andrea Bileck; Johanna C Mader; Samuel M Meier-Menches; Samuel M Gerner; Klaus G Schmetterer; Tobias Pukrop; Albrecht Reichle; Astrid Slany; Christopher Gerner
Journal:  Mol Cell Proteomics       Date:  2017-12-01       Impact factor: 5.911

4.  mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.

Authors:  Wei Mo; Qingxin Liu; Curtis Chun-Jen Lin; Hui Dai; Yang Peng; Yulong Liang; Guang Peng; Funda Meric-Bernstam; Gordon B Mills; Kaiyi Li; Shiaw-Yih Lin
Journal:  Clin Cancer Res       Date:  2015-11-06       Impact factor: 12.531

5.  SIRT2 promotes BRCA1-BARD1 heterodimerization through deacetylation.

Authors:  Elizabeth V Minten; Priya Kapoor-Vazirani; Chunyang Li; Hui Zhang; Kamakshi Balakrishnan; David S Yu
Journal:  Cell Rep       Date:  2021-03-30       Impact factor: 9.423

6.  NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair.

Authors:  Peter V Deraska; Colin O'Leary; Hunter D Reavis; Shelby Labe; Tru-Khang Dinh; Jean-Bernard Lazaro; Christopher Sweeney; Alan D D'Andrea; David Kozono
Journal:  Cell Death Discov       Date:  2018-02-07

Review 7.  HERCing: Structural and Functional Relevance of the Large HERC Ubiquitin Ligases.

Authors:  Jesús García-Cano; Arturo Martinez-Martinez; Joan Sala-Gaston; Leonardo Pedrazza; Jose Luis Rosa
Journal:  Front Physiol       Date:  2019-08-07       Impact factor: 4.566

8.  USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.

Authors:  Qin Lu; Fang-Lin Zhang; Da-Yun Lu; Zhi-Ming Shao; Da-Qiang Li
Journal:  Cancer Med       Date:  2019-09-11       Impact factor: 4.452

9.  Nitrogen Permease Regulator-Like-2 Exhibited Anti-Tumor Effects And Enhanced The Sensitivity Of Colorectal Cancer Cells To Oxaliplatin And 5-Fluorouracil.

Authors:  Aiyun Liu; Jiutao Qiao; Liyuan He; Zhangmeng Liu; Jing Chen; Fenghua Pei; Yaju Du
Journal:  Onco Targets Ther       Date:  2019-10-18       Impact factor: 4.147

10.  Knockout of the epilepsy gene Depdc5 in mice causes severe embryonic dysmorphology with hyperactivity of mTORC1 signalling.

Authors:  James Hughes; Ruby Dawson; Melinda Tea; Dale McAninch; Sandra Piltz; Dominique Jackson; Laura Stewart; Michael G Ricos; Leanne M Dibbens; Natasha L Harvey; Paul Thomas
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.